

AUG 12 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRADEMARK OFFICE  
Application of: Kashmiri et al.  
Application No. 09/830,748

Art Unit: Not yet assigned

Filed: April 30, 2001


For: VARIANTS OF HUMANIZED ANTI-CARCINOMA MAB CC49

Examiner: Not yet assigned

Date: August 7, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on August 7, 2002 as First Class Mail in an envelope addressed to: U.S. PATENT AND TRADEMARK OFFICE, BOX SEQUENCE, P.O. BOX 2327, ARLINGTON, VA 22202

  
Susan Expert Siegel  
Agent for Applicant

U.S. PATENT AND TRADEMARK OFFICE  
BOX SEQUENCE, P.O. BOX 2327  
ARLINGTON, VA 22202

**THIRD PRELIMINARY AMENDMENT**

Prior to examination of the above-referenced application, please amend the application as follows:

*In the Specification:*

Please replace the paragraph at page 4, lines 19-22 with the following:

In particular, the invention relates to variants of HuCC49 in which either L-CDR1 or L-CDR2, or both, are from a human monoclonal antibody (LEN) (LEN L-CDR1 and LEN L-CDR2 correspond to SEQ ID NOS: 7 and 8, respectively). These variants of HuCC49 have the substantially the same affinity constant as HuCC49, or show only a two fold lower relative affinity than that of HuCC49.

Please replace the paragraph at page 5, lines 3-6 with the following:

Figure 2 shows a comparison of the CDR sequences of murine MAb CC49 and humanized MAb HuCC49 with the corresponding CDR sequences of human Mabs LEN and

B2